原发性肝癌现代医学治疗的研究进展  

Research Progress in the Modern Medicine Treatment of Primary Hepatocellular Carcinoma

作　　者：黄赞松[1] 仇仪英[1] 周喜汉[1] 

机构地区：[1]右江民族医学院附属医院消化疾病研究所消化内科,广西百色533000

出　　处：《医学综述》2012年第24期4169-4172,共4页Medical Recapitulate

基　　金：广西自然科学基金(桂科自0542119);广西医疗卫生重点科研课题(桂卫重200887);广西中医药管理局课题(桂卫中gzzc0955)

摘　　要：原发性肝癌是我国最常见的恶性肿瘤之一,近年来,肝癌的基础与临床治疗研究取得较大的进展。外科手术仍是肝癌的首选治疗手段,肝移植是唯一能治愈肝癌的疗法,经导管动脉化疗栓塞术是当前不能手术切除的中晚期肝癌非手术患者的首选,疗效肯定,综合序贯治疗可提高介入疗法的疗效。索拉菲尼是首个被批准用于治疗晚期肝癌的标准药物。现就目前常用的现代医学治疗方法进行总结,探讨其适用范围及优缺点。Primary liver cancer is one of the most common malignant tumors in China.In recent years,greater progress was made in the basic and clinical study on the treatment of liver cancer.Surgical operation is still the primary choice of treatment,and liver transplantation is the only cure.TACE is the preferred method of non-surgical therapy for unresectable advanced hepatocellular carcinoma with affirmative effect,and integrated sequential treatment can improve the efficacy of interventional therapy.Sorafenib is the first standard drug approved for the treatment of advanced liver cancer.Here is to summarize the commonly used treatments of modern medicine at present,exploring the applicable scope,advantages and disadvantages.

关 键 词：原发性肝癌 现代医学 非手术治疗 治疗方法 索拉菲尼 

分 类 号：R735.7[医药卫生—肿瘤]